Overview of the pathogenesis and treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulins

Biologics: Targets and Therapy

Volumn 4, Issue , 2010, Pages 45-49

  Mahdi Rogers, Mohamed ^a   Rajabally, Yusuf A ^a  

^a UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

Author keywords

Chronic inflammatory demyelinating polyneuropathy; Intravenous immunoglobulin; Pathogenesis; Treatment

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BETA1A INTERFERON; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLIC ACID; PLACEBO; PREDNISOLONE;

ANTIINFLAMMATORY ACTIVITY; B LYMPHOCYTE; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL TRIAL; COST OF ILLNESS; DOSE RESPONSE; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG WITHDRAWAL; EVIDENCE BASED PRACTICE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; LOADING DRUG DOSE; MACROPHAGE; NONHUMAN; PATHOPHYSIOLOGY; PLASMAPHERESIS; REVIEW; T LYMPHOCYTE;

EID: 77951148910     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Laughlin RS, Dyck PJ, Melton RJ 3rd, Leibson RC, Ransom J, Dyck PJ. Incidence and prevalence of CIDP and the association of diabetes mel-litus. Neurology. 2009;73:39-45.
2. Rajabally YA, Simpson BS, Beri S, Bankart J, Gosalakal J. Epidemio-logic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: study of a UK population. Muscle Nerve. 2009;39:432-438.
3. Rajabally YA, Chavada G. Lewis-Sumner syndrome of pure upper limb onset: diagnostic, prognostic and therapeutic features. Muscle Nerve. 2009;39:206-220.
4. Said G. Chronic inflammatory demyelinating polyneuropathy. Neuro-muscul Disord. 2006;16:293-303.
5. Waksman BH, Adams RD. A comparative study of experimental allergic neuritis in the rabbit, guinea pig, and mouse. J Neuropathol Exp Neurol. 1956;15:293-334.
6. Lampert PW. Mechanism of demyelination in experimental allergic neuritis. Electron microscopic studies. Lab Invest. 1969;20:127-138.
7. Gabriel CM, Hughes RA, Moore SE, Smith KJ, Walsh FS. Induction of experimental autoimmune neuritis with peripheral myelin protein-22. Brain. 1998;121:1895-1902.
8. Kadlubowski M, Hughes RA. Identification of the neuritogen for experimental allergic neuritis. Nature. 1979;277:140-141.
9. Milner P, Lovelidge CA, Taylor WA, Hughes RA. P0 myelin protein produces experimental allergic neuritis in Lewis rats. J Neurol Sci. 1987;79:275-285.
10. Pollard JD, King RH, Thomas PK. Recurrent experimental allergic neuritis. An electron microscope study. J Neurol Sci. 1975;24:365-383.
11. Harvey GK, Pollard JD, Schindhelm K, Antony J. Chronic experimental allergic neuritis. An electrophysiological and histological study in the rabbit. J Neurol Sci. 1987;81:215-225.
12. Brosnan JV, Craggs RI, King RH, Thomas PK. Attempts to suppress experimental allergic neuritis in the rat by pretreatment with antigen. Acta Neuropathol. 1984;64:153-160.
13. Adam AM, Atkinson PF, Hall SM, Hughes RA, Taylor WA. Chronic experimental allergic neuritis in Lewis rats. Neuropathol Appl Neuro-biol. 1989;15:249-264.
14. Gabriel CM, Gregson NA, Hughes RA. Anti-PMP22 antibod-ies in patients with inflammatory neuropathy. J Neuroimmunol. 2000;104:139-46.
15. Yan WX, Archelos JJ, Hartung HP, Pollard JD. P0 protein is a target antigen in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 2001;50:286-292.
16. Allen D, Giannopoulos K, Gray I, et al. Antibodies to peripheral nerve myelin proteins in chronic inflammatory demyelinating polyradiculo-neuropathy. J Peripher Nerv Syst. 2005;10:174-180.
17. Sanvito L, Makowska A, Mahdi-Rogers M, et al. Humoral and cellular immune responses to myelin protein peptides in chronic inflammatory demyelinating polyradiculoneuropathy1. J Neurol Neurosurg Psychiatry. 2009;80:333-338.
18. Melendez-Vasquez C, Redford J, Choudhary PP, et al. Immunological investigation of chronic inflammatory demyelinating polyradiculoneu-ropathy. J Neuroimmunol. 1997;73:124-134.
19. Bouchard C, Lacroix C, Plante V, et al. Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy. Neurology. 1999;52:498-503.
20. Khalili-Shirazi A, Gregson NA, Londei M, Summers L, Hughes RA. The distribution of CD1 molecules in inflammatory neuropathy. J Neurol Sci. 1998;158:154-163.
21. Kieseier BC, Dalakas MC, Hartung HP. Immune mechanisms in chronic inflammatory demyelinating neuropathy. Neurology. 2002;59: S7-S12.
22. Khalili-Shirazi A, Hughes RA, Brostoff SW, Linington C, Gregson N. T cell responses to myelin proteins in Guillain-Barre syndrome. J Neurol Sci. 1992;111:200-203.
23. Dyck PJ, O'Brien PC, Oviatt KF, et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol. 1982;11:136-141.
24. Dyck PJ, Daube J, O'Brien P, et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med. 1986;314:461-465.
25. Hahn AF, Bolton CF, Pillay N, et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain. 1996;119:1055-1066.
26. Mendell JR, Barohn RJ, Freimer ML, et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradicu-loneuropathy. Neurology. 2001;56:445-449.
27. van Doorn PA, Brand A, Strengers PF, Meulstee J, Vermeulen M. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology. 1990;40:209-212.
28. Choudhary PP, Thompson N, Hughes RA. Improvement following interferon beta in chronic inflammatory demyelinating polyradiculo-neuropathy. J Neurol. 1995;242:252-253.
29. Hadden RD, Sharrack B, Bensa S, Soudain SE, Hughes RA. Randomized trial of interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology. 1999;53:57-61.
30. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001;345:747-755.
31. Imbach P, Barandun S, Baumgartner C, Hirt A, Hofer F, Wagner HP. High-dose intravenous gammaglobulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood. Helv Paediatr Acta. 1981;36:81-86.
32. Kondo N, Kasahara K, Kameyama T, et al. Intravenous immunoglobulins suppress immunoglobulin productions by suppressing Ca(2+)-dependent signal transduction through Fc gamma receptors in B lymphocytes. Scand J Immunol. 1994;40:37-42.
33. Stohl W, Elliot JE. In vitro inhibition by intravenous immunoglobulin of human T cell-dependent B cell differentiation induced by staphylococcal superantigens. Clin Immunol Immunopathol. 1996:79:122-133.
34. Toungouz M, Denys CH, De Groote D, Dupont E. In vitro inhibition of tumour necrosis factor-alpha and interleukin-6 production by intra-venous immunoglobulins. B J Haematol. 1995;89:698-703.
35. Toyoda M, Pao A, Petrosian A, Jordan SC. Pooled human gammaglobu-lin modulates surface molecule expression and induces apoptosis in human B cells. Am J Transplant. 2003;3:156-166.
36. Vassilev T, Gelin C, Kaveri SV, Zilber MT, Boumsell L, Kazatchkine MD. Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg). Clin Exp Immunol. 1993;92:369-372.
37. Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Eng J Med. 1999;34:227-228.
38. Sundblad A, Marcos MA, Malanchere E, et al. Observations on the mode of action of normal immunoglobulin at high doses. Immunol Rev. 1994;139:125-158.
39. Pashov A, Kaveri A, Kazatchkine MD, Bellon B. Suppression of experimental autoimmune encephalomyelitis by intravenous immunoglobulin. In: Kazatchkine MD, Morell A, eds. Intravenous Immunoglobulin: Research and Therapy. New York: Parthenon Publishing; 1996:317-318.
40. Saoudi A, Hurez V, de Kozak Y, et al. Human immunoglobulin preparations for intravenous use prevent experimental autoimmune uveoretinitis. Int Immunol. 1993;5:1559-1567.
41. Basta M, Van Goor F, Luccioli S, et al. F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat Med. 2003;9:431-438.
42. Frank MM, Basta M, Fries LF. The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissues. Clin Immunol Immunopathol. 1992;62:S82-S86.
43. Mollnes TE, Hogasen K, Hoaas BF, Michaelsen TE, Garred P, Harboe M. Inhibition of complement-mediated red cell lysis by immunoglobulins is dependent on the IG isotype and its C1 binding properties. Scand J Immunol. 1995;45:449-456.
44. Dalakas MC. Mechanisms of action of IVIg and therapeutic consider-ations in the treatment of acute and chronic demyelinating neuropathies. Neurology. 2002;59:S13-S21.
45. Vermeulen M, van der Meche FG, Speelman JD, Weber A, Busch HF. Plasma and gamma-globulin infusion in chronic inflammatory poly-neuropathy. J Neurol Sci. 1985;70:317-326.
46. Faed JM, Day B, Pollock M, Taylor PK, Nukada H, Hammond-Tooke GD. High-dose intravenous human immunoglobulin in chronic inflammatory demyelinating polyneuropathy. Neurology. 1989;39:422-425.
47. van Doorn PA, Vermeulen M, Brand A, Mulder PG, Busch HF. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. Clinical and laboratory characteristics associated with improvement. Arch Neurol. 1991;48:217-220.
48. Cornblath DR, Chaudhry V, Griffin JW. Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin. Ann Neurol. 1991;30:104-106.
49. Vermeulen M, van Doorn PA, Brand A, Strengers PF, Jennekens FG, Busch HF. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry. 1993;56:36-39.
50. Hughes R, Bensa S, Willison H, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 2001;50:195-201.
51. Dyck PJ, Litchy WJ, Kratz KM. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 1994;36:838-845.
52. Eftimov F, Winer JB, Vermeulen M, de HR, van S, I. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2009;CD001797.
53. Hughes RA, Donofrio P, Bril V. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 2008;7:136-144.
54. Rajabally YA, Seow H, Wilson P. Dose of intravenous immunoglobulins in chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst. 2006;11:325-329.
55. Gajdos P, Tranchant C, Clair B, et al. Treatment of myasthenia gravis exacerbations with intravenous immunoglobulin: a randomized double-blind clinical trial. Arch Neurol. 2005;62:1689-1693.
56. RMC trial. Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study. Lancet Neurol. 2009;8:158-164.
57. Gorson K, Hughes R, Cros D. Efficacy of interferon beta-1a in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Neurology. 2008;70(suppl 1):A369.
58. Mahdi-Rogers M, Hughes RAC, McCrone P. Economic costs of chronic inflammatory demyelinating radiculoneuropathy, multifocal motor neuropathy and paraproteinaemic demyelinating neuropathy. J Peripher Nervous Syst. 2009;14(s2):94-95.
59. Vucic S, Black K, Baldassari LE, Siao Tick Chong P, Dawson KT, et al. Long-term effects of intravenous immunoglobulin in CIDP. Clin Neu-rophysiol. 2007;118:1980-1984.
60. Borte M, Bernatowska E, Gardulf A, et al. Efficacy and safety of vivaglobin applied subcutaneously to patients with primary immune deficiency (PID). Interim analysis after more than 1300 Infusions. European Society for Immunodeficiencies (ESID) Weimar. 2002.
61. Ochs HD, Gupta S, Kiessling P, Nicolay U, Berger M. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol. 2006;26:265-273.
62. Lee DH, Linker RA, Paulus W, Schneider-Gold C, Chan A, Gold R. Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2008;37:406-409.
63. Koller H, Schroeter M, Feischen H, Hartung HP, Kieseier BC. Subcutaneous self-infusions of immunoglobulins as a potential therapeutic regimen in immune-mediated neuropathies. J Neurol. 2006;253: 1505-1506.
64. Cocito D, Paolasso I, Antonini G, et al. A nationwide retrospective analysis on the effect of immune therapies in patients with chronic demyelinating inflammatory polyradiculoneuropathy. Eur J Neurol. 2009. [Epub ahead of print].
65. Iijima M, Tomita M, Morozumi S, et al. Single nucleotide polymorphism of TAG-1 influences IVIg responsiveness of patients with CIDP. Neurology. 2009;73:1348-1352.